We conducted a retrospective analysis of BRCA1/2-OC survivors, with OC as first cancer diagnosis.
Median age at OC diagnosis for the 69 BRCA1/2-OC survivors was 54 years. Median overall survival was 8 years, being significantly higher for BRCA2 patients than for BRCA1 patients (p = 0.011). Nine patients (13.2%) developed BC at a median age of 61 years. The mean overall BC-free survival was 15.5 years (median not reached). Eight patients (11.8%) underwent bilateral mastectomy (5 simultaneous with BC treatment; 3 RRBBS) at a median age of 56.5 years. The median time from OC to bilateral mastectomy/RRBBS was 5.5 years.
This study adds evidence regarding a lower BC risk after BRCA1/2-OC and higher survival for BRCA2-OC patients. A comprehensive analysis of the competing risks of OC mortality and recurrence against the risk of BC should be individually addressed. Surgical BC risk management may be considered for longer BRCA1/2-OC disease-free survivors. Ultimately, these decisions should always be tailored to patients\' characteristics and preferences.
方法:我们对BRCA1/2-OC幸存者进行了回顾性分析,以OC作为第一个癌症诊断。
结果:69名BRCA1/2-OC幸存者在OC诊断时的中位年龄为54岁。中位总生存期为8年,BRCA2患者明显高于BRCA1患者(p=0.011)。9名患者(13.2%)的中位年龄为61岁。平均总无BC生存期为15.5年(中位数未达到)。8例患者(11.8%)接受了双侧乳房切除术(5例同时接受BC治疗;3例RRBBS),中位年龄为56.5岁。从OC到双侧乳房切除术/RRBBS的中位时间为5.5年。
结论:这项研究增加了关于BRCA1/2-OC后BC风险较低和BRCA2-OC患者生存率较高的证据。应单独解决对OC死亡率和复发与BC风险的竞争性风险的全面分析。对于更长的BRCA1/2-OC无病幸存者,可以考虑进行手术BC风险管理。最终,这些决定应始终根据患者的特征和偏好进行调整。